Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wr-Clinsearch LLC

Neither a doctor nor a teaching hospital

Research payments

$2,435,869

466 payments

Through program year 2025, Wr-Clinsearch LLC is reported as receiving $2,435,869 in research payments, across 466 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $149,087 97
2024 Research $26,240 5
2023 Research $69,954 19
2022 Research $160,080 20
2021 Research $478,379 101
2020 Research $746,210 132
2019 Research $805,919 92

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $1,232,101 212 payments
  2. Ironwood Pharmaceuticals, Inc $309,390 22 payments
  3. AstraZeneca UK Limited $172,503 1 payment
  4. AstraZeneca Pharmaceuticals LP $164,654 13 payments
  5. AbbVie, Inc. $142,937 32 payments
  6. Vanda Pharmaceuticals Inc. $120,630 24 payments
  7. H. Lundbeck A S $60,564 17 payments
  8. Boehringer Ingelheim International GmbH $58,722 62 payments
  9. Kowa Research Institute, Inc. $49,951 32 payments
  10. Moderna TX, Inc. $49,461 26 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 $242,800 3 payments
  2. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $241,078 12 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $239,321 20 payments
  4. McP-103-312 $164,081 8 payments
  5. A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Migraine $135,459 23 payments
  6. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $126,108 22 payments
  7. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis $106,769 22 payments
  8. C3718-301 $100,309 8 payments
  9. Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine $89,774 16 payments
  10. AURORA A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $78,075 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record